Back to Basics: Why, When, and How to Conduct Specialty Toxicology Studies for Eyes, Skin, and Immune System

  • You must log in to register
    • Nonmember - $350
    • Full Member - $225
    • Associate Member - $225
    • Emeritus Member - $225
    • Government Associate Member - $225
    • Government Full Member - $225
    • Postdoctoral Researcher/Transitional Member - $125
    • Student Member - $125

To further its mission to educate, lead, and serve, the American College of Toxicology is proud to offer an eLearning Seminar focused on "Why, When, and How to Conduct Specialty Toxicology Studies." This seminar covers critical topics such as photosafety evaluation, immunotoxicity, dermatotoxicity, and ocular toxicity, which can become crucial during various stages of therapeutic development. These studies may be required due to the route of administration, use case, on/off-target effects, or unexpected findings from nonclinical or clinical studies. Given their complexity, they require specialized experience for proper risk assessment and regulatory success. This four-module eLearning series emphasizes practical principles and uses real-world examples to guide the design and execution of these studies, aiming to ensure success in therapeutic discovery and development.

These modules feature presentations by recognized experts in the field. Modules are available for purchase as a set. Once the live module presentations conclude, registrants will have on-demand access to the modules for 30 days from the time each archive is first accessed. Each module is approximately 90 minutes.

Disclaimer:
This seminar reflects the views of the speaker and should not be construed to represent the views or policies of the American College of Toxicology. Examples presented in this seminar may have required unique strategies that do not necessarily apply to other modalities or situations. Regulatory guidelines and best practices are constantly evolving, and the viewer is encouraged to independently confirm their understanding with what was presented in this seminar.

  • Contains 3 Component(s) Recorded On: 02/27/2025

    Back to Basics Series

    image
    image


    Phototoxic properties of systemically applied pharmaceuticals may be the cause of serious adverse drug reactions. Despite being clinically manageable in principle, they can limit the use of a drug depending on the indication. Protective measures against sunlight can be applied very reasonably during a few days but may not be practicable for chronic treatments. Thus, both patients and health authorities are unlikely to accept a relevant photosensitization risk in such situations.

    Since the global adoption of ICH S10 “Photosafety Evaluation of Pharmaceuticals” in 2013, both the industry and CROs have gained significant experience in conducting risk assessment for phototoxicity potentials for pharmaceuticals. However, it still requires an individual project toxicologist to consider various aspects of a pharmaceutical program to have a staged and integrated analysis of the risk.

    Also, special experience and equipment are needed to conduct compliant studies, for which most of the toxicologists lack hands-on experience. This module focuses on providing details on the in vitro and in vivo studies as part of a tiered testing strategy and providing the scenarios and principles to guide an integrated human risk assessment.

    Daniel Bauer, PhD

    Daniel Bauer, PhD

    Director of Preclinical Safety

    Novartis

    Dr. Daniel Bauer is Director of Preclinical Safety at Novartis in Basel, Switzerland. He is a trained chemist and a board-certified toxicologist with over 20 years of experience in the pharmaceutical industry. Dr. Bauer began his career at Novartis as a lab head in molecular and cellular toxicology, later specializing in photosafety evaluation with a focus on tiered testing strategies from in vitro to in vivo to clinical translation.

    As a study director and monitor, Dr. Bauer has contributed to numerous in vitro safety screening studies, including phototoxicity and genetic toxicity, during candidate selection. He has also supervised in vitro phototoxicity studies under GLP. Currently, he serves as Global Expert in Photosafety, overseeing all photosafety activities at Novartis.

    For EFPIA, Dr. Bauer was a member of the ICH S10 Expert Working Group representing the European pharmaceutical industry. He is currently the chair of the EFPIA Photosafety Working Group, where he facilitates industry-wide knowledge exchange and new initiatives.

    In addition, Dr. Bauer acts as a project toxicologist, working on topical and oral FIH projects in dermatology and oncology indications.

  • Contains 3 Component(s) Recorded On: 03/27/2025

    Back to Basics Series

    image
    image


    With the surge of immunotherapies and gene/cell therapies in the past two decades, the need to conduct immunotoxicity studies has increased dramatically. The studies needed for such programs are often case-by-case, and there is little harmonization between organizations. This module focuses on the considerations, principles, and applicable regulatory guidances to design and conduct an immunotoxicity program for major drug modalities.

    This eLearning module covers several key areas related to immunotoxicity studies. The module will begin with a review of immunotoxicity testing, highlighting the surge in immunotherapies, gene/cell therapies, and the resulting growing need for immunotoxicity studies. The module will discuss the immunotoxicity assays required to support these programs and how the design differs from traditional immunotoxicity testing. Additionally, the module will provide a brief overview of differences in immune responses between nonclinical species and humans. It will also explore the considerations and applicable regulatory guidances for designing immunotoxicity studies for major drug modalities highlighting the case-by-case nature of these studies and the current lack of harmonization between organizations.

    Florence G. Burleson, PhD

    Florence G. Burleson, PhD

    Consultant

    Burleson Research Technologies, Inc.

    Dr. Burleson received her PhD from the Department of Microbiology at the University of Notre Dame and a Master of Science in Financial Management and Technology Commercialization from North Carolina State University (NCSU). She has more than 30 years of professional experience in government, pharmaceutical, and contract research. She is the co-founder of Burleson Research Technologies, Inc. (BRT), a CRO specializing in immunotoxicology. Dr. Burleson has served as a Study Director conducting GLP-compliant studies for immunological, functional, and host resistance immunotoxicity assessments. As Executive VP and Senior Director of Nonclinical Studies, she provides oversight and direction for nonclinical studies programs and is responsible for budgets and financial management at BRT.

    Dr. Burleson is a member of the American College of Toxicology (ACT) and Society of Toxicology (SOT), and a Fellow of the Academy of Toxicological Sciences (ATS). She was elected to the ACT Outreach Committee in 2013 and the ACT Council in 2016. She was Vice-President, President-Elect, and President (2022-2023) of ACT. She has also served on the SOT Finance Committee and is a past President of the SOT Immunotoxicology Specialty Section. Dr. Burleson was Chair of the Scientific Liaison Coalition (SLC), a coalition of societies to increase the impact of the science of toxicology to improve public health. She currently serves on the Editorial Board of the International Journal of Toxicology and on the Editorial Board of Toxicology Research Application.

    Marie-Soleil Piche, PhD

    Marie-Soleil Piche, PhD

    Scientific Director of the Immunology Group

    Charles River Laboratories

    Dr. Marie-Soleil Piche is the Scientific Director of the Immunology group at Charles River Laboratories and specializes in nonclinical and clinical immune safety assessment of biotherapeutic drugs. She obtained her Bachelor’s degree in Immunology at McGill University and her Master of Science in Immunotoxicology at the Armand Frappier Institute. She completed a PhD in the field of autoimmune disease, studying the role of autoantibodies in the pathogenesis of lupus. Prior to joining Charles River, Dr. Piche worked at a small biotech company where she was responsible for developing cell-based assays to study the pharmacodynamics of various biotherapeutic drugs. She is an active member of the HELSI/ITC working group, where she co-leads the Education and Outreach group, and of the APPS, where she participates in the Immunogenicity and qPCR working groups. She is also the past president of the ITSS SOT. Dr. Piche is a co-author on several methods, best practices, and validation white papers.

  • Contains 3 Component(s) Recorded On: 04/10/2025

    Back to Basics Series

    image
    image


    Part 1: In Vitro Assessments and Part 2: Dermal Product Development and Studies

    This eLearning module will focus on the in vitro and in vivo studies needed to support first-in-human clinical trials for pharmaceutical products intended for topical application.

    In vitro early safety screening tools are essential in the initial stages of dermal drug development for identifying potential local toxicities and adverse skin effects. This part of the module will identify available early screening tools that assist in the optimization of both the pharmaceutical and the delivery vehicle. The prominent tools discussed in this module are in vitro skin irritation assays, in vitro skin sensitization assays, and in vitro permeation testing (IVPT). In vitro skin irritation assays identify the potential of drug substances and final formulations to cause local irritation or damage to the skin. In vitro skin sensitization assays evaluate the potential of novel drug substances and formulations to cause allergic reactions on the skin. IVPT assesses the extent of permeation through the skin, allowing determination of local versus systemic exposure with related efficacy and toxicity implications and the influence of different formulations on delivery of the pharmaceutical. Collectively, these assays assist in selecting the optimum drug candidate and formulation for topical use while reducing animal use and the failure of the candidate later in development.

    The module will also discuss the in vivo studies needed to determine both the local and systemic toxicity of dermal pharmaceutical products. These studies generally include the use of the rat as the rodent species and the minipig as the nonrodent species. As the set of in vivo nonclinical studies intended to support dermal administration are quite different from those intended for only systemic administration, these differences will be highlighted. In addition, the regulatory pathways for dermal products will be discussed to provide the differences between a novel dermal product and a previously approved systemic product that is being modified for use in a topical application. Together, this combination of in vitro and in vivo studies will provide a robust safety profile for regulatory agency review in supporting dermal drug development.

    Vincent A. Murphy, PhD, DABT

    Vincent A. Murphy, PhD, DABT

    Director of Toxicology

    STILLMEADOW, Inc.

    Dr. Vincent A. Murphy has over 30 years of experience as a toxicologist while working at Procter & Gamble, Array BioPharma, Inc., and STILLMEADOW, Inc., and as the sole proprietor of a consulting firm, Pharma Toxicology Advisors, LLC. In these positions, he contributed to all developmental phases of drug and other product development from discovery to marketing.

    While at Procter & Gamble and Array BioPharma, Inc., he gained extensive experience in drug discovery and early-stage development of pharmaceuticals for oral, dermal, and injectable routes of administration. Dr. Murphy has designed and monitored studies internally and at contract laboratories that included dermal toxicity, irritation, and sensitization studies in animals and cumulative irritation and sensitization studies in humans. In vitro assays for drug candidate optimization were utilized by Dr. Murphy to assess eye and skin irritation, cytotoxicity, metabolism, genotoxicity, phototoxicity, enzyme induction, and safety pharmacology. He has used in silico programs, like Leadscope and Derek Nexus, for identification of potential toxicities of parent, metabolite, and impurities.

    In his current position as Director of Toxicology at STILLMEADOW, Inc., he also serves as study director for dozens of acute dermal irritation and toxicity studies, local lymph node and Buehler skin sensitization studies, and occasional repeat-dose dermal toxicity studies. The use of in vitro and in silico assays is currently being explored.

    Dr. Murphy earned a BS in Pharmacy from the University of Washington in Seattle and a PhD in Biochemical Pharmacology and Toxicology at the University of Utah in Salt Lake City. He has been a councilor, vice-president, and president of the In Vitro and Alternative Methods Specialty Section in the Society of Toxicology and has served the American College of Toxicology as a member of the Program and Communications Committees and Newsletter Subcommittee, and currently serves as a member of the Education Committee.

    Jeffrey A. Klein, PhD, DABT

    Jeffrey A. Klein, PhD, DABT

    Advisor

    SciLucent, Inc.

    Dr. Jeff Klein is an Advisor in the Nonclinical Safety and Development group at SciLucent, Inc. In this role, he provides scientific and regulatory nonclinical consulting for drug development programs. He was previously a Senior Manager at Noven Pharmaceuticals leading nonclinical programs for transdermal drug development, Director of Preclinical Research at EP Technologies leading a team delivering large molecules through the skin using cold plasma, and Director of Toxicology and Dermatology at Sinclair Research, now Altasciences Preclinical Columbia. Dr. Klein is Past President of the Dermal Specialty Section of the Society of Toxicology and was certified by the American Board of Toxicology in 2012.

  • Contains 3 Component(s) Recorded On: 05/22/2025

    Back to Basics Series

    image
    image


    Ocular toxicity studies of small molecules, biotherapeutics, oligonucleotides, and gene therapies by various routes of administration usually cause adverse ocular effects, especially for intraocular routes (intravitreal, subretinal, intracameral, and suprachoroidal) and less so for the topical ocular route. One critical aspect of ocular toxicity studies is the importance of correlating pathology findings with in-life findings by standard and specialized ophthalmic techniques to guide mitigation and monitoring for ocular adverse events in clinical trials. The advent of ocular sustained-release formulations adds another layer of complexity to identifying ocular effects related to the formulation versus the drug. The contribution of adverse injection procedure-related effects can confound interpretation but does not usually factor into NOAEL determinations. Ocular biotherapeutics and gene therapy drugs are usually immunogenic via innate and/or adaptive responses that may or may not be relevant for human risk assessment. This module will discuss various ocular toxicity studies with practical principles that illustrate the challenges encountered and approaches needed for effective risk assessment and regulatory success with ocular drug development case studies.

    Brian Short, DVM, PhD, DACVP

    Brian Short, DVM, PhD, DACVP

    Consultant

    Brian Short Consulting, LLC

    Dr. Brian Short is a board-certified pathologist with a focus on ocular toxicology, pathology, and ocular drug development. Previously, he was at Allergan (currently AbbVie) as Senior Director of Toxicology and then Pathology following his early career at GlaxoSmithKline (formerly SmithKline Beecham). As an independent consultant since 2016, Dr. Short has consulted on over 160 projects involving ocular drug development of small molecules, biologics, oligonucleotides, and gene and cell therapies, or ocular toxicity of systemic small molecules and biologics. He has authored several seminal publications on ocular toxicology and pathology, served as an invited speaker for over 20 presentations on ocular drug development, and was honored in 2021 with a Career Achievement Award by the Ocular Toxicology Specialty Section of SOT. Currently, Dr. Short is Chair of the Ocular Adversity Working Group sponsored by the STP Scientific and Regulatory Policy Committee. Dr. Short has a DVM from the University of California, Davis; completed a Veterinary Pathology Residency at the University of Florida, Gainesville; earned a PhD in Experimental Pathology from the University of North Carolina, Chapel Hill; and was a Postdoctoral Trainee at the Chemical Industry Institute of Toxicology in Research Triangle Park, NC.

Registration Fees:

Seminar registration is restricted to single person use only. Please note that all eLearning sales are final. No cancellations or refunds will be allotted after payment is processed.

Registration Type Set/Module 1–4
ACT Member $225
ACT Student/Transitional/Postdoctoral Researcher Member $125
Nonmember $350

*Fees are assessed according to membership status at the time of purchase. There are no exceptions and no refunds after payment has been processed.

The Back to Basics: Why, When, and How to Conduct Specialty Toxicology Studies for Eyes, Skin, and Immune System eLearning seminar content will only be available until December 31, 2027.